Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 5/20 | 0.58 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7016060 | 0.88 | ALOX5 (0.64) | ALOX5TMEM97PPARAKMT2AALDH1A1 | |
| SCHEMBL7014446 | 0.79 | HDAC6 (0.47) | KMT2AMEN1NR1D1 | |
| SCHEMBL7018813 | 0.78 | PYGL (0.47) | KMT2AMEN1 | |
| SCHEMBL6733921 | 0.76 | PPARA (0.52) | ALOX5PPARAKMT2AMEN1ALDH1A1 | |
| SCHEMBL7016258 | 0.70 | MEN1 (0.45) | KMT2AMEN1 | |
| SCHEMBL10830747 | 0.69 | ALOX5 (0.72) | ALOX5TMEM97PPARAKMT2AMEN1 | |
| SCHEMBL7014965 | 0.69 | F10 (0.47) | KMT2AMEN1 | |
| SCHEMBL7015590 | 0.69 | F10 (0.47) | KMT2AMEN1 | |
| SCHEMBL2773958 | 0.69 | DYRK1A (0.58) | PPARAKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL24365157 | 0.69 | NPC1 (0.48) | PPARAKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | ALOX5 2020/4885TMEM97 3732/4885PPARA 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.